---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-151049"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2024-05-31T23:59:59+00:00"
generated_at: "2026-06-01T07:08:19.422009+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Karyopharm shareholders approve 6M share increase in equity plan, 5M in ESPP, and option exchange

## Summary
- Stockholders approved Class II directors: Deepika R. Pakianathan, Richard Paulson, Chen Schor (all three-year terms).
- Amendment to 2022 Equity Plan approved: adds 6,000,000 shares for issuance.
- ESPP Amendment approved: adds 5,000,000 shares for issuance.
- Stockholders approved a one-time stock option exchange program for non-executive officer employees.
- Ratified Ernst & Young as independent auditor for FY2024 (87.7M for, 2.5M against).

## SEC filing metadata
- accession: 0001193125-24-151049
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2024-05-31T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312524151049/0001193125-24-151049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312524151049/d827879d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-151049
- JSON: https://secwatch.observer/filing/0001193125-24-151049.json
- Plain text: https://secwatch.observer/filing/0001193125-24-151049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.